Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect-Reference-Cited by-同舟云学术

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

Published:2020-06-17 Issue:10 Volume:75 Page:3084-3086
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Stader Felix¹²^ORCID,Khoo Saye³,Stoeckle Marcel¹²,Back David³,Hirsch Hans H¹⁴,Battegay Manuel¹²,Marzolini Catia¹³

Affiliation:

1. Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland

2. University of Basel, Basel, Switzerland

3. Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

4. Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland

Funder

Swiss National Foundation

Adolf and Mary-Mil Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/75/10/3084/33885409/dkaa253.pdf

Reference10 articles.

1. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19;Cao;N Eng J Med,2020

2. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers;Yeh;J Acquir Immune Defic Syndr,2006

3. A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®;Stader;CPT Pharmacometrics Syst Pharmacol,2019

4. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study;Zhou;Lancet,2020

5. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes;Stader;Clin Pharmacokinet,2019

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of rifampicin administration on CYP induction in a dermatomyositis patient with vasospastic angina attributable to nilmatrelvir/ritonavir-induced blood tacrolimus elevation: A case report;Journal of Infection and Chemotherapy;2024-09

2. A cross-sectional study on the potential drug-drug interaction risk of COVID-19 patients in hospital;Int. Journal of Clinical Pharmacology and Therapeutics;2024-07-01

3. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug–drug interactions;Journal of International Medical Research;2024-05

4. Optimal individualized treatment rule for combination treatments under budget constraints;Journal of the Royal Statistical Society Series B: Statistical Methodology;2024-01-10

5. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir;Clinical Pharmacokinetics;2024-01